Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.
Identifieur interne : 000783 ( Main/Exploration ); précédent : 000782; suivant : 000784Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.
Auteurs : Danuta M. Skowronski [Canada] ; Gaston De Serres ; Jim Dickinson ; Martin Petric ; Annie Mak ; Kevin Fonseca ; Trijntje L. Kwindt ; Tracy Chan ; Nathalie Bastien ; Hugues Charest ; Yan LiSource :
- The Journal of infectious diseases [ 0022-1899 ] ; 2009.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Analyse de séquence d'ADN (MeSH), Canada (épidémiologie), Données de séquences moléculaires (MeSH), Enfant (MeSH), Femelle (MeSH), Glycoprotéine hémagglutinine du virus influenza (composition chimique), Glycoprotéine hémagglutinine du virus influenza (génétique), Grippe humaine (diagnostic), Grippe humaine (prévention et contrôle), Grippe humaine (virologie), Grippe humaine (épidémiologie), Humains (MeSH), Jeune adulte (MeSH), Mâle (MeSH), RT-PCR (MeSH), Sous-type H1N1 du virus de la grippe A (classification), Sous-type H1N1 du virus de la grippe A (génétique), Sous-type H1N1 du virus de la grippe A (immunologie), Sous-type H1N1 du virus de la grippe A (isolement et purification), Sous-type H3N2 du virus de la grippe A (classification), Sous-type H3N2 du virus de la grippe A (génétique), Sous-type H3N2 du virus de la grippe A (immunologie), Sous-type H3N2 du virus de la grippe A (isolement et purification), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Surveillance sentinelle (MeSH), Tests d'inhibition de l'hémagglutination (MeSH), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie), Vaccins inactivés (administration et posologie), Vaccins inactivés (immunologie), Virus influenza B (génétique), Virus influenza B (immunologie), Virus influenza B (isolement et purification).
- MESH :
- administration et posologie : Vaccins antigrippaux, Vaccins inactivés.
- composition chimique : Glycoprotéine hémagglutinine du virus influenza, Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A.
- diagnostic : Grippe humaine.
- génétique : Glycoprotéine hémagglutinine du virus influenza, Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Virus influenza B.
- immunologie : Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Vaccins antigrippaux, Vaccins inactivés, Virus influenza B.
- isolement et purification : Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Virus influenza B.
- prévention et contrôle : Grippe humaine.
- virologie : Grippe humaine.
- épidémiologie : Canada, Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Analyse de séquence d'ADN, Données de séquences moléculaires, Enfant, Femelle, Humains, Jeune adulte, Mâle, RT-PCR, Sujet âgé, Sujet âgé de 80 ans ou plus, Surveillance sentinelle, Tests d'inhibition de l'hémagglutination.
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Canada (epidemiology), Child (MeSH), Female (MeSH), Hemagglutination Inhibition Tests (MeSH), Hemagglutinin Glycoproteins, Influenza Virus (chemistry), Hemagglutinin Glycoproteins, Influenza Virus (genetics), Humans (MeSH), Influenza A Virus, H1N1 Subtype (classification), Influenza A Virus, H1N1 Subtype (genetics), Influenza A Virus, H1N1 Subtype (immunology), Influenza A Virus, H1N1 Subtype (isolation & purification), Influenza A Virus, H3N2 Subtype (classification), Influenza A Virus, H3N2 Subtype (genetics), Influenza A Virus, H3N2 Subtype (immunology), Influenza A Virus, H3N2 Subtype (isolation & purification), Influenza B virus (genetics), Influenza B virus (immunology), Influenza B virus (isolation & purification), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Influenza, Human (diagnosis), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Influenza, Human (virology), Male (MeSH), Middle Aged (MeSH), Molecular Sequence Data (MeSH), Reverse Transcriptase Polymerase Chain Reaction (MeSH), Sentinel Surveillance (MeSH), Sequence Analysis, DNA (MeSH), Vaccines, Inactivated (administration & dosage), Vaccines, Inactivated (immunology), Young Adult (MeSH).
- MESH :
- chemical , administration & dosage : Influenza Vaccines, Vaccines, Inactivated.
- chemical , chemistry : Hemagglutinin Glycoproteins, Influenza Virus.
- geographic , epidemiology : Canada.
- chemical , genetics : Hemagglutinin Glycoproteins, Influenza Virus.
- classification : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype.
- diagnosis : Influenza, Human.
- epidemiology : Influenza, Human.
- genetics : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus, Influenza Vaccines, Vaccines, Inactivated.
- isolation & purification : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Female, Hemagglutination Inhibition Tests, Humans, Male, Middle Aged, Molecular Sequence Data, Reverse Transcriptase Polymerase Chain Reaction, Sentinel Surveillance, Sequence Analysis, DNA, Young Adult.
Abstract
BACKGROUND
Trivalent inactivated influenza vaccine (TIV) is reformulated annually to contain representative strains of 2 influenza A subtypes (H1N1 and H3N2) and 1 B lineage (Yamagata or Victoria). We describe a sentinel surveillance approach to link influenza variant detection with component-specific vaccine effectiveness (VE) estimation.
METHODS
The 2006-2007 TIV included A/NewCaledonia/20/1999(H1N1)-like, A/Wisconsin/67/2005(H3N2)-like, and B/Malaysia/2506/2004(Victoria)-like components. Included participants were individuals >or=9 years of age who presented within 1 week after influenza like illness onset to a sentinel physician between November 2006 and April 2007. Influenza was identified by real-time reverse-transcriptase polymerase chain reaction and/or culture. Isolates were characterized by hemagglutination inhibition assay (HI) and HA1 gene sequence. VE was estimated as 1-[odds ratio for influenza in vaccinated versus nonvaccinated persons].
RESULTS
A total of 841 participants contributed: 69 (8%) were >or=65 years of age; 166 (20%) received the 2006-2007 TIV. Influenza was detected in 337 subjects (40%), distributed as follows: A/H3N2, 242 (72%); A/H1N1, 55 (16%); and B, 36 (11%). All but 1 of the A/H1N1 isolates were well matched, half of A/H3N2 isolates were strain mismatched, and all B isolates were lineage-level mismatched to vaccine. Age-adjusted estimated VE for A/H1N1, A/H3N2, and B components was 92% (95% CI, 40%-91%), 41% (95% CI, 6%-63%), and 19% (95% CI, -112% to 69%), respectively, with an overall VE estimate of 47% (95% CI, 18%-65%). Restriction of the analysis to include only working-age adults resulted in lower VE estimates with wide confidence intervals but similar component-specific trends.
CONCLUSIONS
Sentinel surveillance provides a broad platform to link new variant detection and the composite of circulating viruses to annual monitoring of component-specific VE.
DOI: 10.1086/595862
PubMed: 19086914
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.</title>
<author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name>
<affiliation wicri:level="1"><nlm:affiliation>British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada. danuta.skowronski@bccdc.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>British Columbia Centre for Disease Control, Vancouver, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name>
</author>
<author><name sortKey="Dickinson, Jim" sort="Dickinson, Jim" uniqKey="Dickinson J" first="Jim" last="Dickinson">Jim Dickinson</name>
</author>
<author><name sortKey="Petric, Martin" sort="Petric, Martin" uniqKey="Petric M" first="Martin" last="Petric">Martin Petric</name>
</author>
<author><name sortKey="Mak, Annie" sort="Mak, Annie" uniqKey="Mak A" first="Annie" last="Mak">Annie Mak</name>
</author>
<author><name sortKey="Fonseca, Kevin" sort="Fonseca, Kevin" uniqKey="Fonseca K" first="Kevin" last="Fonseca">Kevin Fonseca</name>
</author>
<author><name sortKey="Kwindt, Trijntje L" sort="Kwindt, Trijntje L" uniqKey="Kwindt T" first="Trijntje L" last="Kwindt">Trijntje L. Kwindt</name>
</author>
<author><name sortKey="Chan, Tracy" sort="Chan, Tracy" uniqKey="Chan T" first="Tracy" last="Chan">Tracy Chan</name>
</author>
<author><name sortKey="Bastien, Nathalie" sort="Bastien, Nathalie" uniqKey="Bastien N" first="Nathalie" last="Bastien">Nathalie Bastien</name>
</author>
<author><name sortKey="Charest, Hugues" sort="Charest, Hugues" uniqKey="Charest H" first="Hugues" last="Charest">Hugues Charest</name>
</author>
<author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19086914</idno>
<idno type="pmid">19086914</idno>
<idno type="doi">10.1086/595862</idno>
<idno type="wicri:Area/Main/Corpus">000801</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000801</idno>
<idno type="wicri:Area/Main/Curation">000801</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000801</idno>
<idno type="wicri:Area/Main/Exploration">000801</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.</title>
<author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name>
<affiliation wicri:level="1"><nlm:affiliation>British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada. danuta.skowronski@bccdc.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>British Columbia Centre for Disease Control, Vancouver, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name>
</author>
<author><name sortKey="Dickinson, Jim" sort="Dickinson, Jim" uniqKey="Dickinson J" first="Jim" last="Dickinson">Jim Dickinson</name>
</author>
<author><name sortKey="Petric, Martin" sort="Petric, Martin" uniqKey="Petric M" first="Martin" last="Petric">Martin Petric</name>
</author>
<author><name sortKey="Mak, Annie" sort="Mak, Annie" uniqKey="Mak A" first="Annie" last="Mak">Annie Mak</name>
</author>
<author><name sortKey="Fonseca, Kevin" sort="Fonseca, Kevin" uniqKey="Fonseca K" first="Kevin" last="Fonseca">Kevin Fonseca</name>
</author>
<author><name sortKey="Kwindt, Trijntje L" sort="Kwindt, Trijntje L" uniqKey="Kwindt T" first="Trijntje L" last="Kwindt">Trijntje L. Kwindt</name>
</author>
<author><name sortKey="Chan, Tracy" sort="Chan, Tracy" uniqKey="Chan T" first="Tracy" last="Chan">Tracy Chan</name>
</author>
<author><name sortKey="Bastien, Nathalie" sort="Bastien, Nathalie" uniqKey="Bastien N" first="Nathalie" last="Bastien">Nathalie Bastien</name>
</author>
<author><name sortKey="Charest, Hugues" sort="Charest, Hugues" uniqKey="Charest H" first="Hugues" last="Charest">Hugues Charest</name>
</author>
<author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name>
</author>
</analytic>
<series><title level="j">The Journal of infectious diseases</title>
<idno type="ISSN">0022-1899</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term>
<term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>Canada (epidemiology)</term>
<term>Child (MeSH)</term>
<term>Female (MeSH)</term>
<term>Hemagglutination Inhibition Tests (MeSH)</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus (chemistry)</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus (genetics)</term>
<term>Humans (MeSH)</term>
<term>Influenza A Virus, H1N1 Subtype (classification)</term>
<term>Influenza A Virus, H1N1 Subtype (genetics)</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza A Virus, H1N1 Subtype (isolation & purification)</term>
<term>Influenza A Virus, H3N2 Subtype (classification)</term>
<term>Influenza A Virus, H3N2 Subtype (genetics)</term>
<term>Influenza A Virus, H3N2 Subtype (immunology)</term>
<term>Influenza A Virus, H3N2 Subtype (isolation & purification)</term>
<term>Influenza B virus (genetics)</term>
<term>Influenza B virus (immunology)</term>
<term>Influenza B virus (isolation & purification)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza, Human (diagnosis)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Influenza, Human (virology)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Molecular Sequence Data (MeSH)</term>
<term>Reverse Transcriptase Polymerase Chain Reaction (MeSH)</term>
<term>Sentinel Surveillance (MeSH)</term>
<term>Sequence Analysis, DNA (MeSH)</term>
<term>Vaccines, Inactivated (administration & dosage)</term>
<term>Vaccines, Inactivated (immunology)</term>
<term>Young Adult (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term>
<term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Analyse de séquence d'ADN (MeSH)</term>
<term>Canada (épidémiologie)</term>
<term>Données de séquences moléculaires (MeSH)</term>
<term>Enfant (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Glycoprotéine hémagglutinine du virus influenza (composition chimique)</term>
<term>Glycoprotéine hémagglutinine du virus influenza (génétique)</term>
<term>Grippe humaine (diagnostic)</term>
<term>Grippe humaine (prévention et contrôle)</term>
<term>Grippe humaine (virologie)</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Humains (MeSH)</term>
<term>Jeune adulte (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>RT-PCR (MeSH)</term>
<term>Sous-type H1N1 du virus de la grippe A (classification)</term>
<term>Sous-type H1N1 du virus de la grippe A (génétique)</term>
<term>Sous-type H1N1 du virus de la grippe A (immunologie)</term>
<term>Sous-type H1N1 du virus de la grippe A (isolement et purification)</term>
<term>Sous-type H3N2 du virus de la grippe A (classification)</term>
<term>Sous-type H3N2 du virus de la grippe A (génétique)</term>
<term>Sous-type H3N2 du virus de la grippe A (immunologie)</term>
<term>Sous-type H3N2 du virus de la grippe A (isolement et purification)</term>
<term>Sujet âgé (MeSH)</term>
<term>Sujet âgé de 80 ans ou plus (MeSH)</term>
<term>Surveillance sentinelle (MeSH)</term>
<term>Tests d'inhibition de l'hémagglutination (MeSH)</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins inactivés (administration et posologie)</term>
<term>Vaccins inactivés (immunologie)</term>
<term>Virus influenza B (génétique)</term>
<term>Virus influenza B (immunologie)</term>
<term>Virus influenza B (isolement et purification)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, Inactivated</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Hemagglutinin Glycoproteins, Influenza Virus</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Canada</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Hemagglutinin Glycoproteins, Influenza Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
<term>Vaccins inactivés</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr"><term>Glycoprotéine hémagglutinine du virus influenza</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
<term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glycoprotéine hémagglutinine du virus influenza</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
<term>Virus influenza B</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins inactivés</term>
<term>Virus influenza B</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
<term>Influenza B virus</term>
<term>Influenza Vaccines</term>
<term>Vaccines, Inactivated</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
<term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
<term>Virus influenza B</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Canada</term>
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Child</term>
<term>Female</term>
<term>Hemagglutination Inhibition Tests</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Molecular Sequence Data</term>
<term>Reverse Transcriptase Polymerase Chain Reaction</term>
<term>Sentinel Surveillance</term>
<term>Sequence Analysis, DNA</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse de séquence d'ADN</term>
<term>Données de séquences moléculaires</term>
<term>Enfant</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>RT-PCR</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Surveillance sentinelle</term>
<term>Tests d'inhibition de l'hémagglutination</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>Trivalent inactivated influenza vaccine (TIV) is reformulated annually to contain representative strains of 2 influenza A subtypes (H1N1 and H3N2) and 1 B lineage (Yamagata or Victoria). We describe a sentinel surveillance approach to link influenza variant detection with component-specific vaccine effectiveness (VE) estimation.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>The 2006-2007 TIV included A/NewCaledonia/20/1999(H1N1)-like, A/Wisconsin/67/2005(H3N2)-like, and B/Malaysia/2506/2004(Victoria)-like components. Included participants were individuals >or=9 years of age who presented within 1 week after influenza like illness onset to a sentinel physician between November 2006 and April 2007. Influenza was identified by real-time reverse-transcriptase polymerase chain reaction and/or culture. Isolates were characterized by hemagglutination inhibition assay (HI) and HA1 gene sequence. VE was estimated as 1-[odds ratio for influenza in vaccinated versus nonvaccinated persons].</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>A total of 841 participants contributed: 69 (8%) were >or=65 years of age; 166 (20%) received the 2006-2007 TIV. Influenza was detected in 337 subjects (40%), distributed as follows: A/H3N2, 242 (72%); A/H1N1, 55 (16%); and B, 36 (11%). All but 1 of the A/H1N1 isolates were well matched, half of A/H3N2 isolates were strain mismatched, and all B isolates were lineage-level mismatched to vaccine. Age-adjusted estimated VE for A/H1N1, A/H3N2, and B components was 92% (95% CI, 40%-91%), 41% (95% CI, 6%-63%), and 19% (95% CI, -112% to 69%), respectively, with an overall VE estimate of 47% (95% CI, 18%-65%). Restriction of the analysis to include only working-age adults resulted in lower VE estimates with wide confidence intervals but similar component-specific trends.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>Sentinel surveillance provides a broad platform to link new variant detection and the composite of circulating viruses to annual monitoring of component-specific VE.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19086914</PMID>
<DateCompleted><Year>2009</Year>
<Month>03</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised><Year>2008</Year>
<Month>12</Month>
<Day>31</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-1899</ISSN>
<JournalIssue CitedMedium="Print"><Volume>199</Volume>
<Issue>2</Issue>
<PubDate><Year>2009</Year>
<Month>Jan</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of infectious diseases</Title>
<ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.</ArticleTitle>
<Pagination><MedlinePgn>168-79</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1086/595862</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Trivalent inactivated influenza vaccine (TIV) is reformulated annually to contain representative strains of 2 influenza A subtypes (H1N1 and H3N2) and 1 B lineage (Yamagata or Victoria). We describe a sentinel surveillance approach to link influenza variant detection with component-specific vaccine effectiveness (VE) estimation.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The 2006-2007 TIV included A/NewCaledonia/20/1999(H1N1)-like, A/Wisconsin/67/2005(H3N2)-like, and B/Malaysia/2506/2004(Victoria)-like components. Included participants were individuals >or=9 years of age who presented within 1 week after influenza like illness onset to a sentinel physician between November 2006 and April 2007. Influenza was identified by real-time reverse-transcriptase polymerase chain reaction and/or culture. Isolates were characterized by hemagglutination inhibition assay (HI) and HA1 gene sequence. VE was estimated as 1-[odds ratio for influenza in vaccinated versus nonvaccinated persons].</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 841 participants contributed: 69 (8%) were >or=65 years of age; 166 (20%) received the 2006-2007 TIV. Influenza was detected in 337 subjects (40%), distributed as follows: A/H3N2, 242 (72%); A/H1N1, 55 (16%); and B, 36 (11%). All but 1 of the A/H1N1 isolates were well matched, half of A/H3N2 isolates were strain mismatched, and all B isolates were lineage-level mismatched to vaccine. Age-adjusted estimated VE for A/H1N1, A/H3N2, and B components was 92% (95% CI, 40%-91%), 41% (95% CI, 6%-63%), and 19% (95% CI, -112% to 69%), respectively, with an overall VE estimate of 47% (95% CI, 18%-65%). Restriction of the analysis to include only working-age adults resulted in lower VE estimates with wide confidence intervals but similar component-specific trends.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Sentinel surveillance provides a broad platform to link new variant detection and the composite of circulating viruses to annual monitoring of component-specific VE.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skowronski</LastName>
<ForeName>Danuta M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo><Affiliation>British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada. danuta.skowronski@bccdc.ca</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>De Serres</LastName>
<ForeName>Gaston</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Dickinson</LastName>
<ForeName>Jim</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Petric</LastName>
<ForeName>Martin</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Mak</LastName>
<ForeName>Annie</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Fonseca</LastName>
<ForeName>Kevin</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kwindt</LastName>
<ForeName>Trijntje L</ForeName>
<Initials>TL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chan</LastName>
<ForeName>Tracy</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bastien</LastName>
<ForeName>Nathalie</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Charest</LastName>
<ForeName>Hugues</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Yan</ForeName>
<Initials>Y</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName>
<AccessionNumberList><AccessionNumber>EU659819</AccessionNumber>
<AccessionNumber>EU659820</AccessionNumber>
<AccessionNumber>EU659821</AccessionNumber>
<AccessionNumber>EU659822</AccessionNumber>
<AccessionNumber>EU659823</AccessionNumber>
<AccessionNumber>EU659824</AccessionNumber>
<AccessionNumber>EU659825</AccessionNumber>
<AccessionNumber>EU659826</AccessionNumber>
<AccessionNumber>EU659827</AccessionNumber>
<AccessionNumber>EU659828</AccessionNumber>
<AccessionNumber>EU659829</AccessionNumber>
<AccessionNumber>EU659830</AccessionNumber>
<AccessionNumber>EU659831</AccessionNumber>
<AccessionNumber>EU659832</AccessionNumber>
<AccessionNumber>EU659833</AccessionNumber>
<AccessionNumber>EU659834</AccessionNumber>
<AccessionNumber>EU659835</AccessionNumber>
<AccessionNumber>EU659836</AccessionNumber>
<AccessionNumber>EU659837</AccessionNumber>
<AccessionNumber>EU659838</AccessionNumber>
<AccessionNumber>EU659839</AccessionNumber>
<AccessionNumber>EU659840</AccessionNumber>
<AccessionNumber>EU659841</AccessionNumber>
<AccessionNumber>EU659842</AccessionNumber>
<AccessionNumber>EU659843</AccessionNumber>
<AccessionNumber>EU659844</AccessionNumber>
<AccessionNumber>EU659845</AccessionNumber>
<AccessionNumber>EU659846</AccessionNumber>
<AccessionNumber>EU659847</AccessionNumber>
<AccessionNumber>EU659848</AccessionNumber>
<AccessionNumber>EU659849</AccessionNumber>
<AccessionNumber>EU659850</AccessionNumber>
<AccessionNumber>EU659851</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Infect Dis</MedlineTA>
<NlmUniqueID>0413675</NlmUniqueID>
<ISSNLinking>0022-1899</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019267">Hemagglutinin Glycoproteins, Influenza Virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Infect Dis. 2009 Jan 15;199(2):155-8</RefSource>
<PMID Version="1">19086916</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019267" MajorTopicYN="N">Hemagglutinin Glycoproteins, Influenza Virus</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName>
<QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018571" MajorTopicYN="Y">Sentinel Surveillance</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2008</Year>
<Month>12</Month>
<Day>18</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2008</Year>
<Month>12</Month>
<Day>18</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>3</Month>
<Day>7</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19086914</ArticleId>
<ArticleId IdType="doi">10.1086/595862</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><noCountry><name sortKey="Bastien, Nathalie" sort="Bastien, Nathalie" uniqKey="Bastien N" first="Nathalie" last="Bastien">Nathalie Bastien</name>
<name sortKey="Chan, Tracy" sort="Chan, Tracy" uniqKey="Chan T" first="Tracy" last="Chan">Tracy Chan</name>
<name sortKey="Charest, Hugues" sort="Charest, Hugues" uniqKey="Charest H" first="Hugues" last="Charest">Hugues Charest</name>
<name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name>
<name sortKey="Dickinson, Jim" sort="Dickinson, Jim" uniqKey="Dickinson J" first="Jim" last="Dickinson">Jim Dickinson</name>
<name sortKey="Fonseca, Kevin" sort="Fonseca, Kevin" uniqKey="Fonseca K" first="Kevin" last="Fonseca">Kevin Fonseca</name>
<name sortKey="Kwindt, Trijntje L" sort="Kwindt, Trijntje L" uniqKey="Kwindt T" first="Trijntje L" last="Kwindt">Trijntje L. Kwindt</name>
<name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name>
<name sortKey="Mak, Annie" sort="Mak, Annie" uniqKey="Mak A" first="Annie" last="Mak">Annie Mak</name>
<name sortKey="Petric, Martin" sort="Petric, Martin" uniqKey="Petric M" first="Martin" last="Petric">Martin Petric</name>
</noCountry>
<country name="Canada"><noRegion><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000783 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000783 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= GrippeCanadaV4 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:19086914 |texte= Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19086914" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a GrippeCanadaV4
This area was generated with Dilib version V0.6.35. |